tbuckley/cabot-search huggingface dataset:
MO66-4 Retrospective study of gastric cancer with myelocarcinomatosis: A novel aspect of treatment for disseminated intravascular coagulation
Authors: Wataru Kusano, Ryosuke Taguchi, Shiho Kawagoe, Keiko Katayose, Takumi Yamaji, Taro Tochigi, Takashi Nakaike, Kiyoshi Yamashita, Yoshihiro Shibata, Shuji Arita
Journal: Annals of Oncology (2023)
MO57-6 Comprehensive genomic profiling is effective in determining treatment decisions for advanced solid tumors patients
Authors: Masaki Ishida, Masahiro Iwasaku, Toshifumi Doi, Takeshi Ishikawa, Akihiro Yosimura, Kenji Morimoto, Shinsaku Tokuda, Young Hak Kim, Tadaaki Yamada, Koichi Takayama
Journal: Annals of Oncology (2023)
MO49-1 The efficacy of high-dose versus intrathecal methotrexate for DLBCL with high risk of CNS relapse: A multicenter retrospective study
Authors: Masahiro Akimoto, Takuya Miyazaki, Hiroyuki Takahashi, Yusuke Saigusa, Takaaki Takeda, Yuto Hibino, Mayumi Tokunaga, Takuma Ohashi, Ayako Matsumura, Haruka Teshigawara, Taisei Suzuki, Hiroshi Teranaka, Yuki Nakajima, Kenji Matsumoto, Chizuko Hashimoto, Katsumichi Fujimaki, Hiroyuki Fujita, Rika Sakai, Shin Fujisawa, Hideaki Nakajima
Journal: Annals of Oncology (2023)
P43-9 The treatment of Kaposi sarcoma: Chasing the progressive disease with the presentation of KICS
Authors: Panuch Eiamprapaporn, Hataiwan Rattanabunjerdkul, Wasithep Limvorapitak, Panchanin Patanayindee, Sutthichai Visutthichaikij, Sasinuch Rutjanawech
Journal: Annals of Oncology (2023)
P54-3 AS101 inhibits tumor metastasis by down-regulation of heparanase
Authors: Fan Wenjun, Che-Hsin Lee
Journal: Annals of Oncology (2023)

Tellurium is a rare element in human body. And ammonium trichloro(dioxoethylene-o,o')tellurate (AS101) is the most bioactive among several synthetic tellurium compounds. After decades of research, AS101 was found to be immunomodulatory which can modulate cytokines. And it also has the ability to reduce the side effect of chemotherapy. However, the effect of AS101 on tumor remains unclear. Probably, application for AS101 as an adjuvant therapy may reduce the side effect of chemotherapy while curing cancer.
MO50-3 Preliminary data from the phase I/II study of TP-3654, an oral PIM-1 kinase inhibitor, in patients with myelofibrosis
Authors: Firas El Chaer, Junichiro Yuda, James Mccloskey, Lindsay Rein, Randy Brown, Steven Green, Jeffrey Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Joseph Scandura, Sujan Kabir, Jason M. Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K. Rampal
Journal: Annals of Oncology (2023)
MO66-2 The use of ramucirumab before nivolumab may improve survival for unresectable advanced or recurrent gastric cancer
Authors: Shoichiro Hirata, Yoshiyasu Kono, Hiromitsu Kanzaki, Shoko Inoo, Sakiko Kuraoka, Katsunori Matsueda, Shotaro Okanoue, Takuya Satomi, Kenta Hamada, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara
Journal: Annals of Oncology (2023)
MO50-5 Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma
Authors: Koji Izutsu, Hideki Goto, Masahiro Kizaki, Masaki Yamaguchi, Noriko Fukuhara, Koji Kato, Toko Saito, Yasuhito Terui, Sumiko Okubo, Tomomi Soshin, Nabanita Mukherjee, Hideyuki Honda, Mohamed Badawi, Jeremy Ross, Kenichi Ishizawa
Journal: Annals of Oncology (2023)

Outcomes for patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) remain poor. We report findings from a phase 2 study of ibrutinib (Ibr) + venetoclax (Ven) in Japanese pts with R/R MCL. This is a phase 2, open-label, single-arm study of Ibr + Ven in Japanese pts aged ≥20 y with R/R MCL (NCT04477486). Pts received Ibr 560 mg + Ven 400 mg (5-wk ramp-up) once daily ≤104 wk. Primary endpoint was complete response (CR) rate (independent review committee [IRC]). Secondary endpoints included overall response rate (ORR; CR + partial response), response duration, undetectable minimal residual disease (uMRD; <0.05%) rate, progression-free survival (PFS), overall survival (OS), and safety (including dose-limiting toxicities [DLTs] in the first 6 pts). The full analysis set (FAS) comprised all treated pts. The per protocol set (PPS) excluded pts with non-evaluable disease at baseline (IRC). Thirteen pts were treated (FAS). Median age was 71 y; pts had a median of 2 prior regimens. The PPS comprised 12 pts. Median treatment duration was 20.4 wk. CR rate and ORR were both 83% (95% CI, 52−98 [PPS]). Median CR duration was not reached (NR). All 6 MRD-evaluable pts with CR had uMRD. Median PFS and OS were NR (FAS; 12-mo PFS and OS rates, 83% and 84%). No DLTs were observed. All 13 pts had ≥1 treatment-emergent adverse event (TEAE) of any grade (Gr); 31% had ≥1 Gr 3/4 TEAE. The most common TEAEs of any Gr (≥30%) were diarrhea (46%) and neutropenia (31%); the most common Gr 3/4 TEAE was neutropenia (23%). One pt discontinued Ibr/Ven due to Gr 3 squamous cell carcinoma of lung (unrelated to Ibr/Ven). Two pts had serious Ibr/Ven-related AEs: Gr 4 sepsis and Gr 3 neutropenia (n=1 each). No pts died due to AEs. Ibr + Ven demonstrated clinically meaningful benefit in Japanese pts with R/R MCL. The safety findings are consistent with the known safety profile of each drug, the underlying disease, and the comorbidities of older pts.
P22-2 A single center treatment experience of combination with chemotherapy and nivolumab for HER2-negative gastric cancer
Authors: Kai Tsugaru, Takeshi Kawakami, Daiki Kawaguchi, Ari Nishimura, Kunihiro Fushiki, Kotoe Oshima, Takahiro Tsushima, Akiko Todaka, Satoshi Hamauchi, Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Kentaro Yamazaki
Journal: Annals of Oncology (2023)
P56-11 Evaluation of the nematode C. elegans cancer test (N-NOSE) in thyroid cancer
Authors: Keisuke Miwa, Toshimitsu Tanaka, Sachiko Nagasu, Hirona Shigyou, Yasutaka Shimotsuura, Hideyuki Hatakeyama, Takaaki Hirotsu
Journal: Annals of Oncology (2023)
MO70-5 The clinical outcomes for anamorelin in advanced gastrointestinal cancer patients with cancer cachexia
Authors: Ari Nishimura, Satoru Hamauchi, Akifumi Notsu, Daiki Kawaguchi, Kai Tsugaru, Kunihiro Fushiki, Kotoe Oshima, Takahiro Tsushima, Takeshi Kawakami, Akiko Todaka, Tomoya Yokota, Hirofumi Yasui, Yusuke Onozawa, Kentaro Yamazaki
Journal: Annals of Oncology (2023)
MO57-1 A phase II study of chemotherapy plus local therapy for non-small cell lung cancer with oligometastases: TORG1529
Authors: Go Saito, Taaaki Tokito, Hidenobu Ishii, Yuichi Takiguchi, Koichi Minato, Hisao Imai, Hiroshi Tanaka, Satoru Miura, Kageaki Watanabe, Yoshihusa Koreeda, Akira Ono, Naoki Furuya, Toshihiro Misumi, Kazushige Hayakawa, Etsuyo Ogo, Kazuhiko Yamada, Hiroaki Okamoto
Journal: Annals of Oncology (2023)
P18-7 Chemotherapy for advanced urachal carcinoma: A case series of three patients
Authors: Takafumi Kitazono, Mamoru Ito, Kenji Tsuchihashi, Taichi Isobe, Takashi Matsumura, Aya Takigawa, Kohei Arimizu, Hiroshi Ariyama, Eishi Baba
Journal: Annals of Oncology (2023)
MO69-3 Pathological predictors of the response to platinum-based chemotherapy in pancreatobiliary neuroendocrine carcinoma
Authors: Takaaki Furukawa, Masato Ozaka, Manabu Takamatsu, Takeshi Okamoto, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takafumi Mie, Tsuyoshi Takeda, Akiyoshi Kasuga, Masato Matsuyama, Takashi Sasaki, Naoki Sasahira
Journal: Annals of Oncology (2023)
MO38-3 EGFR activation elicited adaptive resistance to lorlatinib in ALK-rearranged non-small cell lung cancer cells
Authors: Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Kenji Morimoto, Kazue Yoneda, Mano Horinaka, Toshiyuki Sakai, Hiroaki Ozasa, Koichi Takayama
Journal: Annals of Oncology (2023)
MO34-1 Real-world evidence of precision medicine for biliary tract cancer
Authors: Hideyuki Hayashi, Shigeki Tanishima, Tomoka Fujikura, Kohei Nakamura, Marin Ishikawa, Yasutaka Kato, Ryutaro Kawano, Kenro Hirata, Yasuo Hamamoto, Hiroshi Nishihara
Journal: Annals of Oncology (2023)
MO32-5 Metabolic interaction between gut microbiome and PIK3CA-mutated colorectal cancer: SCRUM-Japan MONSTAR-SCREEN
Authors: Shogen Boku, Shunsuke Sakai, Kentaro Sawada, Satoshi Horasawa, Ayumu Yoshikawa, Yoshiaki Nakamura, Takao Fujisawa, Riu Yamashita, Yoshito Komatsu, Tomohiro Nishina, Manabu Shiozawa, Naohiro Nishida, Kazuhiro Yoshida, Kentaro Yamazaki, Masahiro Goto, Hisateru Yasui, Naoki Takahashi, Shigenori Kadowaki, Tadamichi Denda, Takayuki Yoshino
Journal: Annals of Oncology (2023)
P8-10 WGS analysis of Erbb2-amplified cervical cancer with two simultaneous histologic types: Transdifferentiation hypothesis
Authors: Hiroaki Ikushima, Keita Uchino, Kiyoshi Yamaguchi, Seiya Imoto, Hirotomo Koda, Takuro Mizukami, Teppei Morikawa, Yoichi Furukawa
Journal: Annals of Oncology (2023)
P38-8 Phase 1/2 study of menin inhibitor DSP-5336 in acute leukemia with and without MLL rearrangement or NPM1 mutation
Authors: Naval Daver, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry Erba, John Affinito, Hongliang Cai, Emily Brooks, Ken Eguchi, Jay Stoudemire, Akinobu Watanabe, Takahiro Kuwaki, Matthew Hitron, Philip Komarnitsky, Junichiro Yuda
Journal: Annals of Oncology (2023)
MO48-5 Progression of disease within 5 months of adult T-cell leukemia-lymphoma (ATL5) as a clinical endpoint for high-risk mortality outcomes
Authors: Haruhiko Sano, Hiroo Katsuya, Valcarcel Bryan, Atae Utsunomiya, Maki Otsuka, Masaharu Miyahara, Kenji Ishitsuka, Yasushi Takamatsu, Junji Suzumiya, Kazuo Tamura, J Enriquez Daniel, Castro Denisse, E Beltran Brady, Idrobo Henry, Pena Camila, Fiad Lorena, Carlos Ramos Juan, Malpica Castillo Luis, Shinya Kimura
Journal: Annals of Oncology (2023)
P40-3 Retrospective analysis of amrubicin therapy for advanced or recurrent neuroendocrine carcinoma in our facility
Authors: Akira Tsunoda, Koshi Sukeno, Hiroki Oka, Yasutaka Tono, Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Yoshiki Yamashita, Toshiro Mizuno, Isao Tawara
Journal: Annals of Oncology (2023)
MO50-4 Efficacy and safety of commercially approved BCMA-targeting CAR-T therapy in triple-class refractory multiple myeloma
Authors: Noriko Nishimura, Samantha Brown, M. Devlin Sean, Dahi Parastoo, J. Landau Heather, B. Lahoud Oscar, Scordo Michael, L. Shah Gunjan, J. Chung David, Hassoun Hani, Hultcrantz Malin, Korde Neha, M. Lesokhin Alexander, Mailankody Sham, A. Shah Urvi, R. Tan Carlyn, Z. Usmani Saad, Sergio A. Giralt
Journal: Annals of Oncology (2023)
P59-3 Psychiatric adverse effects of corticosteroid among cancer patients: Systematic review of case report, prospective study
Authors: Gisela Meydilin Sanjaya, Felix Wijovi, Natasya Reina, Rivaldo Steven Heriyanto, Angeline Tancherla, Fernando Dharmaraja, Patricia Angel, Darien Alfa Cipta, Andree Kurniawan
Journal: Annals of Oncology (2023)
P18-5 Examination of the sequence of chemotherapy regimen in malignant pleural mesothelioma
Authors: Yoshiki Negi, Taiichiro Otsuki, Naoki Kawamura, Misa Murakami, Takashi Kandori, Misaki Morishita, Zyotaro Kiyota, Takashi Nishimura, Akichika Nagano, Mayuko Tokuda, Tomoki Higashiyama, Daisuke Horio, Koji Mikami, Toshiyuki Minami, Ryo Takahashi, Kozo Kuribayashi, Takashi Kijima
Journal: Annals of Oncology (2023)
MO21-2 High incidence of cancer therapeutics-related cardiac dysfunction in the patients with cardiac sarcoma
Authors: Koki Uehara, Shohei Moriyama, Hitoshi Kusaba, Kanami Furukawa, Kohei Arimizu, Hirofumi Oomura, Mamoru Ito, Kenji Tuchihashi, Taichi Isobe, Hiroshi Ariyama, Mitunori Fukata, Koichi Akashi, Eishi Baba
Journal: Annals of Oncology (2023)
MO20-3 Outcome of parameningeal head and neck rhabdomyosarcoma in adults: Kyushu Medical Oncology Group Study
Authors: Taichi Isobe, Kenji Tsuchihashi, Shohei Ueno, Ryosuke Taguchi, Mamoru Ito, Michitaka Nakano, Hiroshi Ariyama, Fumiyasu Hanamura, Yuta Okumura, Masato Komoda, Taito Esaki, Shuji Arita, Kenta Nio, Hitoshi Kusaba, Kazuki Hashimoto, Tadamasa Yoshitake, Yoshinao Oda, Koichi Akashi, Eishi Baba
Journal: Annals of Oncology (2023)
MO21-5 Chemotherapy regimen of Kaposi sarcoma in HIV/AIDS patients: A systematic review of randomized controlled trials
Authors: Andree Kurniawan, Chandra Sari, Devi Astri Rivera Amelia, Deden Djatnika, Muhammad Arman Nasution, Rivaldo Steven Heriyanto, Felix Wijovi, Alexander Erick Purnomo, Ikhwan Rinaldi
Journal: Annals of Oncology (2023)
MO19-6 The use of ctDNA analysis in predicting esophageal cancer recurrence: A systematic review and meta-analysis
Authors: Celine Augla D'Prinzessin, Naufal Nandita Firsty, Bahagia Willibrordus Maria Nainggolan, Endi Taris Pasaribu, Adi Muradi Muhar
Journal: Annals of Oncology (2023)
MO19-4 Impact of tislelizumab on health-related quality of life in Asian patients with esophageal squamous cell carcinoma
Authors: Ken Kato, Eric Van Cutsem, Jaffer Ajani, Lin Shen, Gisoo Barnes, Ningning Ding, Aiyang Tao, Tianyu Xia, Lin Zhan, Sung-Bae Kim
Journal: Annals of Oncology (2023)
MO9-3 Triple-negative and hormone-positive breast cancer: The association with reproductive factors among Bangladeshi women
Authors: Muhammad Rafiqul Islam, Hongxu Zhu, Syeda Masuma Siddiqua, Syed Mohammad Ariful Islam, Atm Kamrul Hasan, Beauty Saha, Nargis Akter, Nazrina Khatun, James P. Long, Naoto T. Ueno
Journal: Annals of Oncology (2023)
MO11-6 Characteristics of patients with pneumocystis pneumonia during cancer chemotherapy enrolled in the institutional serious adverse event database
Authors: Hideki Tsujimura, Sachiko Kamagata, Kayo Sekine, Masakatsu Akiba, Kiyoto Kuwabara, Naomi Kiuchi, Toshiko Miyaki, Hiroshi Ishii
Journal: Annals of Oncology (2023)
MO9-1 Clinical characteristics of HER2-low stage I triple-negative breast cancer
Authors: Tomomi Sanomachi, Hitomi Okuma Shumiyoshi, Rui Kitadai, Asuka Kawachi, Shu Yazaki, Momoko Tokura, Motoko Arakaki, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Aiko Maejima, Yuki Kojima, Tadaaki Nishikawa, Kazuki Sudo, Tatsunori Shimoi, Emi Noguchi, Yasuhiro Fujiwara, Akihiko Suto, Kan Yonemori
Journal: Annals of Oncology (2023)
MO10-2 Clinical decisions by the Molecular Tumor Board on comprehensive genomic profiling tests in Japan: A retrospective observational study
Authors: Hidekazu Shirota, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Hiroshi Tada, Muneaki Shimada, Tetsuya Niihori, Yoko Aoki, Ikuko Sugiyama, Maako Kawamura, Jun Yasuda, Shuhei Suzuki, Takeshi Iwaya, Motonobu Saito, Tsuyoshi Saito, Toru Furukawa, Chikashi Ishioka
Journal: Annals of Oncology (2023)
Impaired glycine neurotransmission causes adolescent idiopathic scoliosis
Authors: Xiaolu Wang, Ming Yue, Jason Pui Yin Cheung, Prudence Wing Hang Cheung, Yanhui Fan, Meicheng Wu, Xiaojun Wang, Sen Zhao, Anas M. Khanshour, Jonathan J. Rios, Zheyi Chen, Xiwei Wang, Wenwei Tu, Danny Chan, Qiuju Yuan, Dajiang Qin, Guixing Qiu, Zhihong Wu, Terry Jianguo Zhang, Shiro Ikegawa, Nan Wu, Carol A. Wise, Yong Hu, Keith Dip Kei Luk, You-Qiang Song, Bo Gao
Journal: Journal of Clinical Investigation (2023)

Adolescent idiopathic scoliosis (AIS) is the most common form of spinal deformity, affecting millions of adolescents worldwide, but it lacks a defined theory of etiopathogenesis. Because of this, treatment of AIS is limited to bracing and/or invasive surgery after onset. Preonset diagnosis or preventive treatment remains unavailable. Here, we performed a genetic analysis of a large multicenter AIS cohort and identified disease-causing and predisposing variants of SLC6A9 in multigeneration families, trios, and sporadic patients. Variants of SLC6A9, which encodes glycine transporter 1 (GLYT1), reduced glycine-uptake activity in cells, leading to increased extracellular glycine levels and aberrant glycinergic neurotransmission. Slc6a9 mutant zebrafish exhibited discoordination of spinal neural activities and pronounced lateral spinal curvature, a phenotype resembling human patients. The penetrance and severity of curvature were sensitive to the dosage of functional glyt1. Administration of a glycine receptor antagonist or a clinically used glycine neutralizer (sodium benzoate) partially rescued the phenotype. Our results indicate a neuropathic origin for "idiopathic" scoliosis, involving the dysfunction of synaptic neurotransmission and central pattern generators (CPGs), potentially a common cause of AIS. Our work further suggests avenues for early diagnosis and intervention of AIS in preadolescents.
MO9-4 Cognitive decline after receiving endocrine therapy and/or chemotherapy in breast cancer patients: A systematic review
Authors: Angeline Tancherla, Felix Wijovi, Patricia Angel, Rivaldo Steven Heriyanto, Natasya Reina, Gisela Meydilin Sanjaya, Fernando Dharmaja, Darien Alfa Cipta, Andree Kurniawan
Journal: Annals of Oncology (2023)
MO9-5 Psychological interventions for managing depression among post intervention breast cancer patients: A systematic review
Authors: Fernando Dharmaraja, Felix Wijovi, Patricia Angel, Rivaldo Steven Heriyanto, Natasya Reina, Gisela Meydilin Sanjaya, Angeline Tancherla, Darien Alfa Cipta
Journal: Annals of Oncology (2023)

In Indonesia, Breast cancer it the most common cancer in women. While receiving treatment, complication of psychological problems such as depression arises. This condition may negatively affect the prognosis of therapy. Psychological intervention is known as one of effective treatment modalities for depression. This review will evaluate the psychological interventions in managing depression particularly among breast cancer patients.
MO11-1 Phase I dose-finding study of the SIRPα inhibitor BI 765063 as monotherapy in Japanese patients with advanced cancer
Authors: Toshihiko Doi, Kenjiro Aogi, Motohiro Tamiya, Eric Block, Yoshifumi Tachibana, Akiko Sarashina, Noboru Yamamoto
Journal: Annals of Oncology (2023)
MO8-5 Pneumocystis jiroveci pneumonia in patients receiving ddAC for breast cancer: A single center retrospective study
Authors: Chika Manako, Rikiya Nakamura, Satoshi Yoshimura, Tamaki Tamanuki, Shouko Hayama, Toshiko Miyaki, Keiko Oshida, Masaki Oshida, Yasushi Ito, Hideki Tsujimura, Kyoya Kumagai, Naohito Yamamoto
Journal: Annals of Oncology (2023)
Agent-Regret in Healthcare
Authors: Gavin Enck, Beth Condley
Journal: The American Journal of Bioethics (2023)

For healthcare professionals and organizations, there is an emphasis on addressing moral distress and compassion fatigue among clinicians. While addressing these issues is vital, this paper suggests that the philosophical concept of agent-regret is a relevant but overlooked issue in healthcare. To experience agent-regret is to regret your harmful but not wrongful actions. This person's action results in someone being killed or significantly injured, but it was ethically faultless. Despite being faultless, agent-regret is an emotional response concerning one's agency in a situation that results in death or significant harm. In healthcare, many clinicians are likely to experience regret for faultless actions that significantly harm or cause the death of a patient. The recognition of agent-regret in healthcare is significant because it differs, conceptually and practically, from moral distress and compassion fatigue. Building on the work of Wojtowicz (2022), we should strive to understand clinicians' agent-regret by recognizing their agency in the situation, not lessening or removing it.
Severe Respiratory Disease Among Children With and Without Medical Complexity During the COVID-19 Pandemic
Authors: Christina Belza, Eleanor Pullenayegum, Katherine E. Nelson, Kazuyoshi Aoyama, Longdi Fu, Francine Buchanan, Sanober Diaz, Ori Goldberg, Astrid Guttmann, Charlotte Moore Hepburn, Sanjay Mahant, Rachel Martens, Apsara Nathwani, Natasha R. Saunders, Eyal Cohen
Journal: JAMA Network Open (2023)

Severe respiratory disease declined during the COVID-19 pandemic, partially due to decreased circulation of respiratory pathogens. However, the outcomes of children with higher risk have not been described using population-based data.
Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant—Reply
Authors: Ajit P. Limaye, Barbara Haber
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant
Authors: Ilies Benotmane, Peggy Perrin, Sophie Caillard
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal